Form 4: Haemonetics EVP Michelle Basil Reports Stock and Option Awards

Michelle Basil, EVP and General Counsel of Haemonetics, reports the acquisition of restricted stock units and stock options.

Summary

• Michelle Basil, an EVP and General Counsel at Haemonetics Corp, filed a Form 4 on May 20, 2025.
• The report details transactions from May 16, 2025, including the acquisition of 5,689 shares of common stock in the form of restricted stock units (RSUs).
• Basil also acquired 12,317 non-qualified stock options with an exercise price of $70.31.
• The RSUs vest in three equal annual installments starting on the first anniversary of the grant date.
• The stock options vest in annual increments of 25% beginning on the first anniversary of the grant date and expire on 05/16/2032.
• Following these transactions, Basil beneficially owns 34,167 shares of common stock and 12,317 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock and option awards, indicating standard executive compensation practices.

Positives

• The acquisition of RSUs and stock options suggests confidence in the company's future performance from the perspective of an executive.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a multi-year incentive structure for the executive.

Industry Context

Insider transactions are routinely monitored to gauge executive sentiment and potential future performance of the company. This filing is a standard disclosure required by the SEC.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns executive interests with company performance.

Key Dates

Keywords

Form 4, insider trading, stock options, restricted stock units, executive compensation, Haemonetics, HAE, Basil, Michelle Basil